Attached files
| file | filename |
|---|---|
| 8-K - 8-K - INTERMOLECULAR INC | a12-10572_18k.htm |
Exhibit 99.1
INTERMOLECULAR ANNOUNCES FIRST QUARTER 2012 FINANCIAL RESULTS
Achieved a Consecutive Quarter of Positive Non-GAAP Net Income — Contract Renewals and Expansions Pave the Way for Continued Growth in 2012
SAN JOSE, Calif. — April 26, 2012 — Intermolecular, Inc. (NASDAQ: IMI)—accelerating research and development (R&D) for semiconductor and clean-energy industries—today announced results for its first quarter ended March 31, 2012.
Revenue for the first quarter of 2012 was $16.4 million, representing 40% growth on a year-over-year basis. Collaborative development program (or CDP) revenue was $12.2 million for the quarter, compared to $7.8 million in the prior year, in part due to an increase in our development program for advanced logic semiconductors, and the initiation of new micro-CDP engagements in the clean energy sector. Licensing and royalty revenue was $3.5 million, compared to $3.2 million for the same period a year ago. Workflow product revenue of $0.7 million was consistent with the $0.7 million recognized in the prior year quarter.
For the first quarter of 2012, the Company reported a net loss of $(0.2) million or $(0.00) per share, compared to a net loss of $(5.3) million, or $(0.93) per share for the first quarter of 2011. Net loss for the first quarter of 2011 includes a $(4.0) million expense associated with the accretion of convertible, redeemable preferred shares, equivalent to $(0.72) per share.
Intermolecular reports revenue, costs of revenue, gross margin, operating income (loss), net income (loss) and earnings per share in accordance with GAAP and additionally on a non-GAAP basis. A reconciliation of the difference between the non-GAAP financial measures with the most directly comparable GAAP measure, as well as a description of the items excluded from the non-GAAP measures, is included in the financial statements portion of this press release.
On a non-GAAP basis, the Company reported net income of $0.6 million or $ 0.01 per share, compared to a net loss of $(0.6) million, or $(0.10) per share in the first quarter of 2011.
“We are pleased with the extension and expansion of our customer programs with Toshiba, SanDisk, and Guardian Industries in the first quarter of 2012, which confirms our technical contributions to these key customers. These contracted engagements build the foundation for meaningful year over year revenue growth in 2012,” said David Lazovsky, President and CEO of Intermolecular. “While the ongoing reorganization of Elpida introduces uncertainty over the timing and magnitude of volume-based royalties from this customer, we believe the low-power, mobile DRAM technology that we are developing in this collaborative program has significant value to the DRAM industry.”
Intermolecular ended the first quarter of 2012 with backlog that is expected to be recognized as revenue over the remainder of 2012 of $43.1 million. When combined with actual revenue of $16.4 million in the first quarter of 2012, backlog at the end of the first quarter of 2012 provides total revenue visibility of approximately $59.5 million for the current year. This compares to $47.2 million in expected revenue out of backlog for 2012 that the Company reported at the end of the prior quarter.
Outlook for Second Quarter 2012
The following statements are based on current expectations for the second quarter of 2012. These statements are forward-looking and actual results may differ materially depending on factors set forth under “Forward Looking Statements” below.
· The Company projects revenue in the range of $14.5 to $15.0 million. This revenue projection includes $14.5 million from our March 31, 2012 reported backlog.
· Non-GAAP net loss, excluding stock-based compensation expense, is projected between a non-GAAP loss of $(1.0) million to $(0.5) million, or between $(0.02) — $(0.01) per share, on approximately 42.9 million shares outstanding.
Conference Call Today
Intermolecular will hold a conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time today with David Lazovsky, President and Chief Executive Officer, and Peter Eidelman, Chief Financial Officer, to discuss first quarter 2012 results.
The call can be accessed by dialing (877) 251-1860; international callers should dial (224) 357-2386. Please dial-in ten minutes prior to the scheduled conference call time. A live and archived webcast of the call will be available on Intermolecular’s Website at http://ir.intermolecular.com for up to 30 days after the call.
About Intermolecular, Inc.
Intermolecular® has pioneered a proprietary approach to accelerate research and development, innovation, and time-to-market for the semiconductor and clean-energy industries. The approach consists of the Company’s proprietary High Productivity Combinatorial (HPCTM) platform, coupled with its multi-disciplinary team. Through paid collaborative development programs (CDPs) with its customers, Intermolecular develops proprietary technology and intellectual property for its customers focused on advanced materials, processes, integration and device architectures. Founded in 2004, Intermolecular is based in San Jose, California. “Intermolecular” and the Intermolecular logo are registered trademarks; and “HPC” and “Tempus” are trademarks of Intermolecular, Inc.; all rights reserved. Learn more at www.intermolecular.com.
# # #
Forward-Looking Statements
Statements in the press release that are not historical facts are “forward-looking statements” within the meaning the Private Securities Litigation Reform Act of 1995. These forward looking statements may be identified by terms such as believe, expect, may, will, provide, could and should and the negative of these terms or other similar expressions. These statements, including statements relating to expectations of future revenue, gross margin, net loss, and stock-based compensation expense, as well as expectations regarding recognition in our 2012 revenue of our current backlog. These forward-looking statements and all other statements that may be made in this press release that are not historical facts, are subject to a number of risks and uncertainties that may cause actual results to differ materially. These forward-looking statements reflect only Intermolecular’s views as of today’s date, and although these forward-looking statements are based upon information available as of the date hereof and reflect management’s good faith beliefs, they inherently involve known and unknown risks, uncertainties, and other factors that may cause actual events, results, performance or achievements to differ materially from anticipated. Important factors that could cause actual results to differ materially from expectations are disclosed in Intermolecular’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K filed on March 16, 2012, particularly in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” filed with the SEC and available at www.sec.gov. You should read Intermolecular’s SEC filings and the documents that are filed with the SEC as exhibits to those filings, with the understanding that Intermolecular’s actual future results, levels of activity, performance and achievements may be materially different from what we expect.
Intermolecular, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts, Unaudited)
|
|
|
Three Months Ended March 31, |
| ||||
|
|
|
2012 |
|
2011 |
| ||
|
|
|
|
|
|
| ||
|
Revenue: |
|
|
|
|
| ||
|
Collaborative development program and services revenue |
|
$ |
12,195 |
|
$ |
7,793 |
|
|
Product revenue |
|
678 |
|
678 |
| ||
|
Licensing and royalty revenue |
|
3,509 |
|
3,217 |
| ||
|
Total revenue |
|
16,382 |
|
11,688 |
| ||
|
Cost of revenue |
|
7,188 |
|
5,516 |
| ||
|
Gross profit |
|
9,194 |
|
6,172 |
| ||
|
|
|
|
|
|
| ||
|
Operating expenses: |
|
|
|
|
| ||
|
Research and development |
|
5,068 |
|
4,519 |
| ||
|
Sales and marketing |
|
1,240 |
|
905 |
| ||
|
General and administrative |
|
2,818 |
|
1,799 |
| ||
|
Total operating expenses |
|
9,126 |
|
7,223 |
| ||
|
|
|
|
|
|
| ||
|
Operating income (loss) |
|
68 |
|
(1,051 |
) | ||
|
Interest (expense) income, net |
|
(249 |
) |
4 |
| ||
|
Other expense, net |
|
(6 |
) |
(178 |
) | ||
|
Loss before provision for income taxes |
|
(187 |
) |
(1,225 |
) | ||
|
Income tax (benefit) provision |
|
(1 |
) |
1 |
| ||
|
Net loss |
|
(186 |
) |
(1,226 |
) | ||
|
Accretion on redeemable convertible preferred stock |
|
— |
|
(4,041 |
) | ||
|
Net loss attributable to common stockholders |
|
$ |
(186 |
) |
$ |
(5,267 |
) |
|
|
|
|
|
|
| ||
|
Basic and diluted net loss per common share |
|
$ |
(0.00 |
) |
$ |
(0.93 |
) |
|
|
|
|
|
|
| ||
|
Shares used in basic and diluted net loss per common share |
|
42,241 |
|
5,633 |
| ||
Intermolecular, Inc.
Condensed Consolidated Balance Sheets
(In thousands, Unaudited)
|
|
|
As of March 31, |
|
As of |
| ||
|
|
|
2012 |
|
2011 |
| ||
|
ASSETS |
|
|
|
|
| ||
|
Current assets: |
|
|
|
|
| ||
|
Cash and cash equivalents |
|
$ |
80,847 |
|
$ |
81,002 |
|
|
Marketable securities |
|
1,251 |
|
— |
| ||
|
Total cash, cash equivalents and marketable securities |
|
82,098 |
|
81,002 |
| ||
|
Accounts receivable, net |
|
6,066 |
|
11,162 |
| ||
|
Inventory, current portion |
|
1,797 |
|
— |
| ||
|
Prepaid expenses and other current assets |
|
1,383 |
|
1,763 |
| ||
|
Total current assets |
|
91,344 |
|
93,927 |
| ||
|
|
|
|
|
|
| ||
|
Inventory, net of current portion |
|
2,433 |
|
2,532 |
| ||
|
Property and equipment, net |
|
24,147 |
|
25,128 |
| ||
|
Intangible assets, net |
|
5,996 |
|
6,067 |
| ||
|
Other assets |
|
162 |
|
160 |
| ||
|
Total assets |
|
$ |
124,082 |
|
$ |
127,814 |
|
|
|
|
|
|
|
| ||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
| ||
|
Current liabilities: |
|
|
|
|
| ||
|
Accounts payable |
|
$ |
906 |
|
$ |
1,079 |
|
|
Accrued compensation and employee benefits |
|
2,078 |
|
2,452 |
| ||
|
Deferred revenue, current portion |
|
8,652 |
|
11,168 |
| ||
|
Accrued liabilities |
|
3,075 |
|
3,759 |
| ||
|
Note payable, current portion |
|
928 |
|
804 |
| ||
|
Total current liabilities |
|
15,639 |
|
19,262 |
| ||
|
|
|
|
|
|
| ||
|
Note payable, net of current portion |
|
26,276 |
|
26,514 |
| ||
|
Deferred revenue, net of current portion |
|
161 |
|
716 |
| ||
|
Other long-term liabilities |
|
1,049 |
|
1,149 |
| ||
|
Total liabilities |
|
43,125 |
|
47,641 |
| ||
|
|
|
|
|
|
| ||
|
Stockholders’ equity: |
|
|
|
|
| ||
|
Common stock |
|
42 |
|
42 |
| ||
|
Additional paid-in capital |
|
181,650 |
|
180,680 |
| ||
|
Accumulated deficit |
|
(100,735 |
) |
(100,549 |
) | ||
|
Total stockholders’ equity |
|
80,957 |
|
80,173 |
| ||
|
Total liabilities and stockholders’ equity |
|
$ |
124,082 |
|
$ |
127,814 |
|
Intermolecular, Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands, Unaudited)
|
|
|
Three Months Ended March 31, |
| ||||
|
|
|
2012 |
|
2011 |
| ||
|
Cash flows from operating activities: |
|
|
|
|
| ||
|
Net loss |
|
$ |
(186 |
) |
$ |
(1,226 |
) |
|
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|
|
|
|
| ||
|
Depreciation and amortization |
|
1,852 |
|
1,508 |
| ||
|
Stock-based compensation |
|
827 |
|
406 |
| ||
|
Revaluation of preferred stock warrant liability |
|
— |
|
235 |
| ||
|
Changes in operating assets and liabilities: |
|
|
|
|
| ||
|
Prepaid expenses and other assets |
|
385 |
|
262 |
| ||
|
Inventory |
|
(1,698 |
) |
109 |
| ||
|
Accounts receivable |
|
5,096 |
|
(435 |
) | ||
|
Accounts payable |
|
(412 |
) |
(702 |
) | ||
|
Accrued and other liabilities |
|
(1,044 |
) |
(396 |
) | ||
|
Deferred revenue |
|
(3,071 |
) |
(4,130 |
) | ||
|
Net cash provided by (used in) operating activities |
|
1,749 |
|
(4,369 |
) | ||
|
Cash flows from investing activities: |
|
|
|
|
| ||
|
Purchase of short-term investments |
|
(1,251 |
) |
— |
| ||
|
Purchase of property and equipment |
|
(333 |
) |
(3,321 |
) | ||
|
Capitalized intangible assets |
|
(327 |
) |
(179 |
) | ||
|
Net cash used in investing activities |
|
(1,911 |
) |
(3,500 |
) | ||
|
Cash flows from financing activities: |
|
|
|
|
| ||
|
Payment of debt |
|
(114 |
) |
— |
| ||
|
Proceeds from exercise of common stock options |
|
121 |
|
15 |
| ||
|
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs |
|
— |
|
14,927 |
| ||
|
Net cash provided by financing activities |
|
7 |
|
14,942 |
| ||
|
Net (decrease) increase in cash and cash equivalents |
|
(155 |
) |
7,073 |
| ||
|
Cash and cash equivalents at beginning of period |
|
81,002 |
|
23,064 |
| ||
|
Cash and cash equivalents at end of period |
|
$ |
80,847 |
|
$ |
30,137 |
|
Non-GAAP Financial Measures
To supplement the financial data presented on a GAAP basis, we also disclose certain non-GAAP financial measures, which exclude the effect of stock-based compensation. These non-GAAP financial measures are not in accordance with GAAP, and do not serve as an alternative to GAAP. These results should only be used to evaluate our results of operations in conjunction with the corresponding GAAP measures. We believe that our non-GAAP financial information provides useful information to management and investors regarding financial and business trends relating to our financial condition and results of operations because the non-GAAP measures exclude charges that management considers to be outside of Intermolecular’s core operating results. We believe that the non-GAAP measures of revenue, costs of revenue, gross margin, operating income (loss), net income (loss) and earnings per share, viewed in combination with our financial results calculated in accordance with GAAP, provide investors with additional perspective and a more meaningful understanding of our ongoing operating performance. In addition, management uses these non-GAAP measures to review and assess the financial performance of the Company, to determine executive officer incentive compensation and to plan and forecast performance in future periods. Our non-GAAP measurements are not prepared in accordance with GAAP, and are not an alternative to GAAP financial information, and may be calculated differently than non-GAAP financial information disclosed by other companies.
Intermolecular, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands, except per share amounts, Unaudited)
|
|
|
Three Months Ended March 31, 2012 |
| |||||||
|
|
|
GAAP |
|
Stock- |
|
Non-GAAP |
| |||
|
|
|
|
|
|
|
|
| |||
|
Revenue: |
|
|
|
|
|
|
| |||
|
Collaborative development program and services revenue |
|
$ |
12,195 |
|
$ |
— |
|
$ |
12,195 |
|
|
Product revenue |
|
678 |
|
— |
|
678 |
| |||
|
Licensing and royalty revenue |
|
3,509 |
|
— |
|
3,509 |
| |||
|
Total revenue |
|
16,382 |
|
— |
|
16,382 |
| |||
|
Cost of revenue (a) |
|
7,188 |
|
(284 |
) |
6,904 |
| |||
|
Gross profit |
|
9,194 |
|
284 |
|
9,478 |
| |||
|
|
|
|
|
|
|
|
| |||
|
Operating expenses: |
|
|
|
|
|
|
| |||
|
Research and development (a) |
|
5,068 |
|
(209 |
) |
4,859 |
| |||
|
Sales and marketing (a) |
|
1,240 |
|
(125 |
) |
1,115 |
| |||
|
General and administrative (a) |
|
2,818 |
|
(209 |
) |
2,609 |
| |||
|
Total operating expenses |
|
9,126 |
|
(543 |
) |
8,583 |
| |||
|
|
|
|
|
|
|
|
| |||
|
Operating income |
|
68 |
|
827 |
|
895 |
| |||
|
Interest (expense) income, net |
|
(249 |
) |
— |
|
(249 |
) | |||
|
Other expense, net |
|
(6 |
) |
— |
|
(6 |
) | |||
|
Income (loss) before provision for income taxes |
|
(187 |
) |
827 |
|
640 |
| |||
|
Income tax benefit |
|
(1 |
) |
— |
|
(1 |
) | |||
|
Net (loss) income |
|
$ |
(186 |
) |
$ |
827 |
|
$ |
641 |
|
|
|
|
|
|
|
|
|
| |||
|
Basic net (loss) income per common share |
|
$ |
(0.00 |
) |
|
|
$ |
0.02 |
| |
|
Diluted net (loss) income per common share |
|
$ |
(0.00 |
) |
|
|
$ |
0.01 |
| |
|
|
|
|
|
|
|
|
| |||
|
Shares used in basic net (loss) income per common share |
|
42,241 |
|
|
|
42,241 |
| |||
|
Shares used in diluted net (loss) income per common share |
|
42,241 |
|
|
|
46,875 |
| |||
(a) Reflects the stock-based compensation expense recorded relating to stock-based awards. The Company excludes this item when it evaluates the continuing operational performance of the Company as management believes this GAAP measure is not indicative of its core operating performance.
Intermolecular, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(In thousands, except per share amounts and percentages, Unaudited)
|
|
|
Three Months Ended March 31, |
| ||||
|
|
|
2012 |
|
2011 |
| ||
|
|
|
|
|
|
| ||
|
GAAP cost of net revenue |
|
$ |
7,188 |
|
$ |
5,516 |
|
|
Stock-based compensation expense (a) |
|
(284 |
) |
(95 |
) | ||
|
Non-GAAP cost of net revenue |
|
$ |
6,904 |
|
$ |
5,421 |
|
|
|
|
|
|
|
| ||
|
GAAP gross profit |
|
$ |
9,194 |
|
$ |
6,172 |
|
|
Stock-based compensation expense (a) |
|
284 |
|
95 |
| ||
|
Non-GAAP gross profit |
|
$ |
9,478 |
|
$ |
6,267 |
|
|
|
|
|
|
|
| ||
|
As a percentage of net revenue: |
|
|
|
|
| ||
|
GAAP gross margin |
|
56.1 |
% |
52.8 |
% | ||
|
Non-GAAP gross margin |
|
57.9 |
% |
53.6 |
% | ||
|
|
|
|
|
|
| ||
|
GAAP operating income (loss) |
|
$ |
68 |
|
$ |
(1,051 |
) |
|
Stock-based compensation expense (a): |
|
|
|
|
| ||
|
- Cost of net revenue |
|
284 |
|
95 |
| ||
|
- Research and development |
|
209 |
|
67 |
| ||
|
- Sales and marketing |
|
125 |
|
131 |
| ||
|
- General and administrative |
|
209 |
|
113 |
| ||
|
Non-GAAP operating income (loss) |
|
$ |
895 |
|
$ |
(645 |
) |
|
|
|
|
|
|
| ||
|
GAAP net loss attributable to common stockholders |
|
$ |
(186 |
) |
$ |
(5,267 |
) |
|
Stock-based compensation expense (a) |
|
827 |
|
406 |
| ||
|
Preferred stock warrant charges (b) |
|
— |
|
235 |
| ||
|
Accretion on redeemable convertible preferred stock |
|
— |
|
4,041 |
| ||
|
Non-GAAP net income (loss) attributable to common stockholders |
|
$ |
641 |
|
$ |
(585 |
) |
|
|
|
|
|
|
| ||
|
Shares used in computing Non-GAAP basic earnings per share (c) |
|
42,241 |
|
5,633 |
| ||
|
|
|
|
|
|
| ||
|
Shares used in computing Non-GAAP diluted earnings per share |
|
46,875 |
|
5,633 |
| ||
|
|
|
|
|
|
| ||
|
Non-GAAP earnings per share: |
|
|
|
|
| ||
|
Basic net income (loss) per common share |
|
$ |
0.02 |
|
$ |
(0.10 |
) |
|
|
|
|
|
|
| ||
|
Diluted net income (loss) per common share |
|
$ |
0.01 |
|
$ |
(0.10 |
) |
(a) Reflects the stock-based compensation expense recorded relating to stock-based awards. The Company excludes this item when it evaluates the continuing operational performance of the Company as management believes this GAAP measure is not indicative of its core operating performance.
(b) Change in fair value of preferred stock warrants prior to their exercise in connection with the Company’s initial public offering in November 2011.
(c) Basic common shares during the first quarter of 2012 were 42.2 million compared to 5.6 million basic common shares during the first quarter of 2011. This increase in share count year over year includes the conversion of preferred shares to common in connection with the Company’s initial public offering in November 2011 as well as new shares issued as part of the Company’s Series E Preferred Stock financing and the Company’s initial public offering completed in 2011.
Press Contact
Ed Korczynski, Intermolecular
Marketing Communications Director
edk@intermolecular.com
+1.408.582.5629
Investor Relations Contact
Gary Hsueh, Intermolecular
Sr. Director of Corporate Development and Investor Relations
gary.hsueh@intermolecular.com
+1.408.582.5635
Source: Intermolecular